SynthesisBMC oral health2026
A network meta-analysis of randomized controlled trials evaluating the evidence of pharmacological agents and growth factors in the regeneration of bony defects in chronic periodontitis.
Synthesis in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeriodontitis is a chronic, multifactorial infectious disease affecting the oral cavity, destroying the periodontal supporting tissues, including alveolar bone resorption and loss of clinical attachment. These changes can result in the formation of intrabony defects and if left untreated, it can ultimately result in tooth loss. To enhance periodontal regeneration, several pharmacologic agents-alendronate (ALN), rosuvastatin (RSV), atorvastatin (ATV), metformin (MF), and melatonin (ML)-have demonstrated promising osteoanabolic and anti-inflammatory effects. When combined with platelet-rich fibrin (PRF), these agents may further enhance clinical and radiographic outcomes. This study aimed to assess the adjunctive benefits of various drug-PRF combinations on clinical attachment level (CAL) gain and bone fill (BF) in chronic periodontitis patients.
methodsThis network meta-analysis (NMA) adhered to PRISMA-NMA standards and was recorded in the PROSPERO registry (CRD42024600432). An extensive literature search was conducted using the PubMed/ Medline, Wiley Online Library, Embase, and CENTRAL databases identified randomized controlled trials (RCTs) published after 2016. The analysis included ten studies comprising RCTs with 393 participants containing intrabony or furcation region defects and follow-up periods of 6 and 9 months.
resultsPRF with MF demonstrated the highest efficacy for CAL gain (SUCRA 1.00), followed by PRF with ALN (0.60) and RSV (0.70). For bone fill, PRF with ALN ranked highest (SUCRA 0.90), followed by RSV (0.90) and MF (0.60). ML and ATV combinations showed modest effects, while PRF alone and placebo consistently ranked lowest (SUCRA ≤ 0.20).
conclusionsPRF combined with MF, ALN, and RSV appears to be the most effective therapeutic option for managing bony defects in chronic periodontitis. Future studies should confirm these findings through additional large and long-term clinical trials. CLINICAL RELEVANCE: The study provides clinically relevant evidence supporting the adjunctive use of pharmacologic agents with PRF to optimize regenerative outcomes. Such combinations can improve bone fill and attachment gain, offering predictable benefits for patients with chronic periodontitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.